



PRESS RELEASE Contact: Michael Senken
Phone: (678) 384-6720

MiMedx to Attend International Society for the Advancement of Spine Surgery Annual Meeting

Marietta, GA, April 21, 2011 (PR Newswire) – MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today the Company's attendance at the upcoming International Society for the Advancement of Spine Surgery Annual Meeting, April 26 – 29, 2011. The meeting will be held at the Venetian Congress Center, located within the Venetian / Palazzo Hotels in Las Vegas, Nevada.

MiMedx will highlight two technologies focusing on spinal surgery, HydroFix™ Vaso Shield and AmnioFix™ Amniotic Membrane Allografts in the exhibition hall. In addition to exhibiting, during the Scientific Session, data on both technologies will be presented to surgeons regarding their use for spinal surgery. MiMedx will also take this opportunity to meet with new and existing domestic and international distribution partners.

MiMedx Group will be located in Booth 236 at the Venetian Congress Center.

About MiMedx

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants manufactured from human amniotic membrane. The Company has an experienced team poised to capitalize on its science and technology to generate rapid sales growth and profitability. Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures. Our platform technologies, HydroFix™ and CollaFix™, and our newest platform technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures and MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.

###